Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Friday, June 30, 2023.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q1 FY2023 (2023-06-30): -92.25%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-37.74%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Psyence Biomedical Ltd.
Market Cap
$95475.00
Return on Invested Capital (ROIC)
N/A
TTM Avg
-37.74%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110112.00
Return on Invested Capital (ROIC)
N/A
TTM Avg
-1903.66%
3Y Avg
-964.53%
5Y Avg
-810.80%
Market Cap
$70884.00
Return on Invested Capital (ROIC)
-53.95%
TTM Avg
-378.25%
3Y Avg
-240.67%
5Y Avg
-168.66%
Market Cap
$61172.00
Return on Invested Capital (ROIC)
-242.09%
TTM Avg
-168.38%
3Y Avg
-134.24%
5Y Avg
-96.72%
Market Cap
$30389.00
Return on Invested Capital (ROIC)
-27.17%
TTM Avg
-13.97%
3Y Avg
-24.41%
5Y Avg
-14.32%
Market Cap
$29771.00
Return on Invested Capital (ROIC)
-116.42%
TTM Avg
-219.31%
3Y Avg
-171.50%
5Y Avg
-182.90%
Market Cap
$6235.00
Return on Invested Capital (ROIC)
N/A
TTM Avg
-57.80%
3Y Avg
-12.89%
5Y Avg
-12.89%
Market Cap
$250443.00
Return on Invested Capital (ROIC)
-152.82%
TTM Avg
-117.29%
3Y Avg
-102.27%
5Y Avg
-113.28%
Market Cap
$378849.00
Return on Invested Capital (ROIC)
-83.46%
TTM Avg
-94.98%
3Y Avg
-93.88%
5Y Avg
-93.88%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Psyence Biomedical Ltd. (PBM) | $95475.00 | N/A | -37.74% | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $110112.00 | N/A | -1903.66% | -964.53% | -810.80% |
| PRF Technologies Ltd. (PRFX)vs › | $70884.00 | -53.95% | -378.25% | -240.67% | -168.66% |
| Akanda Corp. (AKAN)vs › | $61172.00 | -242.09% | -168.38% | -134.24% | -96.72% |
| Zhongchao Inc. (ZCMD)vs › | $30389.00 | -27.17% | -13.97% | -24.41% | -14.32% |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $29771.00 | -116.42% | -219.31% | -171.50% | -182.90% |
| NewGenIvf Group Limited (NIVF)vs › | $6235.00 | N/A | -57.80% | -12.89% | -12.89% |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | -152.82% | -117.29% | -102.27% | -113.28% |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | -83.46% | -94.98% | -93.88% | -93.88% |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | -10.38% | -17.82% | -53.65% | -61.91% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2023-06-30 | -92.25% |
| 2023-03-31 | -95.03% |
| 2022-12-31 | -0.58% |
| 2022-09-30 | -0.47% |
| 2022-06-30 | -0.37% |
| 2022-03-31 | -0.13% |
| 2021-12-31 | 0.00% |
